Figure 2. Base-Case Analysis Showing 10-Year Fiscal Impact of Glucagon-Like Peptide-1 Receptor Agonists on Medicare Expenditures for Obesity Treatment.
This figure presents the projected 10-year fiscal impact of glucagon-like peptide-1 receptor agonists on Medicare expenditures for obesity treatment from 2026 to 2035. The bars represent 3 key components of fiscal impact: medication costs, obesity-related health savings, and net spending.
